tiprankstipranks

Apellis price target raised to $96 from $86 at Baird

Baird analyst Colleen Kusy raised the firm’s price target on Apellis to $96 from $86 and keeps an Outperform rating on the shares. The firm noted the company reported better-than-expected, positive results for subq pegcetacoplan in two rare, serious kidney diseases (C3G/IC-MPGN) which adds $50M peak opportunity to Baird’s model.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue